Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

909 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.
Madera S, Izzo F, Chervo MF, Dupont A, Chiauzzi VA, Bruni S, Petrillo E, Merin SS, De Martino M, Montero D, Levit C, Lebersztein G, Anfuso F, Roldán Deamicis A, Mercogliano MF, Proietti CJ, Schillaci R, Elizalde PV, Cordo Russo RI. Madera S, et al. Among authors: de martino m. Cell Death Dis. 2023 Dec 15;14(12):833. doi: 10.1038/s41419-023-06339-1. Cell Death Dis. 2023. PMID: 38102106 Free PMC article. No abstract available.
MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Venturutti L, Cordo Russo RI, Rivas MA, Mercogliano MF, Izzo F, Oakley RH, Pereyra MG, De Martino M, Proietti CJ, Yankilevich P, Roa JC, Guzmán P, Cortese E, Allemand DH, Huang TH, Charreau EH, Cidlowski JA, Schillaci R, Elizalde PV. Venturutti L, et al. Among authors: de martino m. Oncogene. 2016 Dec 1;35(48):6189-6202. doi: 10.1038/onc.2016.151. Epub 2016 May 9. Oncogene. 2016. PMID: 27157613 Free PMC article.
TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G, Frahm I, Allemand DH, Deza EG, Ares S, Gercovich FG, Guzmán P, Roa JC, Elizalde PV, Schillaci R. Mercogliano MF, et al. Among authors: de martino m. Clin Cancer Res. 2017 Feb 1;23(3):636-648. doi: 10.1158/1078-0432.CCR-16-0970. Epub 2016 Oct 3. Clin Cancer Res. 2017. PMID: 27698002
Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
Mercogliano MF, Inurrigarro G, De Martino M, Venturutti L, Rivas MA, Cordo-Russo R, Proietti CJ, Fernández EA, Frahm I, Barchuk S, Allemand DH, Figurelli S, Deza EG, Ares S, Gercovich FG, Cortese E, Amasino M, Guzmán P, Roa JC, Elizalde PV, Schillaci R. Mercogliano MF, et al. Among authors: de martino m. BMC Cancer. 2017 Dec 28;17(1):895. doi: 10.1186/s12885-017-3897-x. BMC Cancer. 2017. PMID: 29281999 Free PMC article.
Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy.
De Martino M, Tkach M, Bruni S, Rocha D, Mercogliano MF, Cenciarini ME, Chervo MF, Proietti CJ, Dingli F, Loew D, Fernández EA, Elizalde PV, Piaggio E, Schillaci R. De Martino M, et al. Oncoimmunology. 2020 Jan 29;9(1):1715767. doi: 10.1080/2162402X.2020.1715767. eCollection 2020. Oncoimmunology. 2020. PMID: 32064174 Free PMC article.
Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth.
Chervo MF, Cordo Russo RI, Petrillo E, Izzo F, De Martino M, Bellora N, Cenciarini ME, Chiauzzi VA, Santa María de la Parra L, Pereyra MG, Güttlein LN, Podhajcer OL, Daniotti JL, Dupont A, Barchuk S, Figurelli S, Lopez Della Vecchia D, Roa JC, Guzmán P, Proietti CJ, Schillaci R, Elizalde PV. Chervo MF, et al. Among authors: de martino m. Oncogene. 2020 Sep;39(39):6245-6262. doi: 10.1038/s41388-020-01430-9. Epub 2020 Aug 25. Oncogene. 2020. PMID: 32843720
Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.
Madera S, Izzo F, Chervo MF, Dupont A, Chiauzzi VA, Bruni S, Petrillo E, Merin SS, De Martino M, Montero D, Levit C, Lebersztein G, Anfuso F, Roldán Deamicis A, Mercogliano MF, Proietti CJ, Schillaci R, Elizalde PV, Cordo Russo RI. Madera S, et al. Among authors: de martino m. Cell Death Dis. 2022 May 9;13(5):447. doi: 10.1038/s41419-022-04855-0. Cell Death Dis. 2022. PMID: 35534460 Free PMC article.
Correction: MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Venturutti L, Russo RIC, Rivas MA, Mercogliano MF, Izzo F, Oakley RH, Pereyra MG, De Martino M, Proietti CJ, Yankilevich P, Roa JC, Guzmán P, Cortese E, Allemand DH, Huang TH, Charreau EH, Cidlowski JA, Schillaci R, Elizalde PV. Venturutti L, et al. Among authors: de martino m. Oncogene. 2023 Dec;42(50):3719. doi: 10.1038/s41388-023-02870-9. Oncogene. 2023. PMID: 37978227 No abstract available.
909 results